Overview

Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

Status:
Completed
Trial end date:
2002-07-30
Target enrollment:
0
Participant gender:
All
Summary
To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Imperial College London
Treatments:
Lamivudine
Zidovudine
Criteria
Inclusion Criteria:

- HTLV-I-associated myelopathy

Exclusion Criteria:

- prior exposure to zidovudine or lamivudine on disease modifying therapy

- under age 16